RxDoctor Payments Data

Peter Friedman, MD

Clinical Cardiac Electrophysiology · Hyannis, MANPI 1841398252

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (35.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Johnson & Johnson at 42.6% of the total. Reporting peaked in 2019 at $9,991 and has fallen 79.5% since, to $2,047 in 2025.

$17,945in general payments, 2019–2025

Across 576 payments — averaging $31.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$8K
  • Abbott$4K
  • Boston Scientific$3K
  • Medtronic$3K
  • E.r. Squibb & Sons, L.L.C.$124
  • Novartis$74
  • plus $191 from 8 others
$15,625in research payments, 2019–2025

Across 15 payments — averaging $1041.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$16K

What the payments were for

  • Speaking & faculty fees$6,30035%
  • Travel & lodging$6,12934%
  • Food & beverage$5,51031%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,945 in reported general payments places this provider in the 60th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$203,520
Medicare patients
2,941
Services billed
4,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$172,008
XareltoRivaroxaban77$114,162
MultaqDronedarone Hcl30$58,906
Flecainide Acetate173$8,721
Propafenone Hcl110$6,287
Propafenone Hcl ErPropafenone Hcl16$3,479
Dofetilide12$3,125
Amiodarone Hcl118$2,427
Metoprolol Succinate140$2,254
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$940
SotalolSotalol Hcl12$123
Metoprolol Tartrate12$79
Cephalexin27$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$7,644$114,16277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →